|1.||Kasparkova, Jana: 2 articles (11/2010 - 07/2006)|
|2.||Brabec, Viktor: 2 articles (11/2010 - 07/2006)|
|3.||Gibson, Dan: 2 articles (11/2010 - 07/2006)|
|4.||Renwick, A G: 2 articles (12/2003 - 01/2000)|
|5.||Vrana, Oldrich: 1 article (11/2010)|
|6.||Suchankova, Tereza: 1 article (11/2010)|
|7.||Kostrhunova, Hana: 1 article (11/2010)|
|8.||Park, Min Kyoung: 1 article (02/2010)|
|9.||Jun, Yong Joo: 1 article (02/2010)|
|10.||Lee, Hwa Jeong: 1 article (02/2010)|
02/25/2010 - "In particular, the cyclic phosphazene trimer platinated with a hydrophobic cis-bis(cyclohexylamine)Pt-moiety forms very stable polymersomes with excellent tumor selectivity by EPR effect and seems to be a promising candidate for preclinical studies."
05/01/1999 - "The rectal absorption of a platinum anti-tumor agent, [bis (acetato) ammine dichloro (cyclohexylamine) platinum(IV)] (BMS-182751), was investigated in rats. "
05/01/1999 - "Rectal absorption of [Bis (acetato) ammine dichloro (cyclohexylamine) platinum(IV)] (BMS-182751), a new anti-tumor agent, in rats."
12/01/1995 - "A series of cyano- and carboxyborane adducts of cyclohexylamines and toluidines were shown to be cytotoxic towards suspended single cell tumors. "
12/20/2002 - "cis-trans-cis-Ammine(cyclohexylamine)diacetatodichloroplatinum(IV) is an oral analog of the platinum anti-cancer drug cisplatin that is currently in phase III clinical trials. "
04/01/1990 - "The morphogenesis of cyclohexylamine-induced testicular atrophy in the rat: in vivo and in vitro studies."
04/01/1989 - "The pharmacokinetics of cyclohexylamine make an important contribution to the difference in sensitivity to testicular atrophy in rats and mice and the dose-response relationship for this toxicity in rats."
04/01/1989 - "After 7 and 13 weeks testicular atrophy was demonstrated in both strains of rats given cyclohexylamine diet by a decrease in organ weight and by histological changes. "
01/01/2000 - "Measurements of terminal cyclohexylamine concentrations showed that three of the males dosed with cyclamate at 500 mg/kg were high converters, with plasma concentrations comparable to the levels that produce testicular atrophy in rats. "
01/01/1989 - "Concern over the safety of cyclamates arises from observations that some individuals and experimental animals can metabolize cyclamate to cyclohexylamine and that cyclohexylamine has been shown to produce testicular atrophy in experimental animals. "
|3.||Body Weight (Weight, Body)
02/20/1970 - "In another study in which 50 rats were fed daily 15 milligrams of cyclohexylamine sulfate per kilogram of body weight for 2 years, eight males and nine females survived. "
04/01/1990 - "Male Wistar strain rats were fed a diet providing an intake of 0 or 400 mg cyclohexylamine (CHA)/kg body weight/day for 1, 3, 7, 9, or 13 weeks. "
06/01/1983 - "The possible embryotoxic effects of cyclohexylamine hydrochloride doses (expressed as free base) of 10, 30 and 100 mg/kg of body weight per day administered orally in water to mice and rats from the 6th to 15th day post-coitum were investigated. "
07/01/1976 - "Cyclohexylamine sulphate, administered 5 times at 150 mg/kg body-weight orally, had no mutagenic effect, whereas cyclophosphamide, adminstered 5 times at 100 mg/kg body-weight orally, had a chromosome-damaging effect on Chinese hamster spermatogonia."
12/01/1994 - "Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines."
01/01/1994 - "Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro."
12/01/1994 - "active lipophilic platinum drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) was generated in the 41M and CH1 human ovarian carcinoma cell lines, and their resistance mechanisms were compared to parallel cisplatin-resistant (cisR) cell lines. "
10/01/1994 - "Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)]."
11/15/1992 - "Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines."
|4.||satraplatin (JM 216)
|8.||DNA (Deoxyribonucleic Acid)
|9.||dimethylamine (dimethylamine nitrate)
|10.||HMGB1 Protein (HMG1)